To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: Beyfortus (nirsevimab) 50 mg Open for Ordering & Upcoming Webinar
Date: August 18, 2025
Beyfortus (nirsevimab) 50 mg Open for Ordering
The Maine Immunization Program is pleased to announce that Beyfortus (nirsevimab) 50 mg for infants is now open for ordering through ImmPact. This is open to all enrolled Vaccines for Children (VFC) providers for the 2025-2026 RSV season (October 2025 – March 2026).
-
Maximum Order Quantity: 50 doses per site (per season).
-
Nirsevimab 100 mg: Remains available at a maximum quantity of 75 doses per order.
-
Separate Orders Required: Nirsevimab orders MUST be placed separately from regular vaccines in ImmPact; combined orders will be denied.
Immunization Recommendations
-
Infants (Under 8 Months): All infants entering their first RSV season should receive a single dose of nirsevimab unless their mother received an RSV vaccine during pregnancy.
-
Children (8-19 Months): High-risk children (premature, chronic lung disease or severe immunocompromised) should receive 200 mg before their second RSV season.
Nirsevimab Storage
-
Store syringes between 36°F to 46°F and use them within 8 hours if stored at room temperature. Discard if not used in time.
Administration with Other Vaccines
Documentation in ImmPact
-
Administered doses must be documented in ImmPact within 5 business days.
-
ImmPact will not forecast nirsevimab doses, due to the complexity of ACIP’s recommendations.
Product Expiration and Inventory Guidance
-
All remaining doses of nirsevimab distributed in Maine during the 2024-2025 respiratory syncytial virus (RSV) season will expire in 2025 or 2026 depending on lot.
-
Providers should use remaining inventory first at the start of the 2025-2026 RSV season, ensuring doses are stored at the appropriate temperature.
Update to the Upcoming Respiratory Season Educational Webinar
The Maine Immunization Program (MIP) will host its annual Respiratory Season Educational Lunch and Learn Webinar on Thursday, September 18, 2025 @ 12:00 PM.
This webinar will be presented by our Vaccines for Children (VFC) and Adult Vaccine Education teams and will provide an overview of the vaccines available through MIP and the Adult 317 Program for this upcoming 2025 – 2026 respiratory season.
The webinar will include:
-
RSV Vaccine for Infants and Adults: Overview of RSV vaccinations available for infants and adults for the 2025-2026 respiratory season.
-
NEW RSV Product: Introduction to the newest available monoclonal antibody product, Enflonsia (clesrovimab) for infants (not yet available - MIP will update providers once ordering is available through ImmPact).
-
COVID-19 & Influenza Vaccines: Review of the most up-to-date recommendations for the upcoming season.
-
Q&A Session: Opportunity for providers to ask questions about respiratory vaccine availability through MIP.
Webinar Details:
-
Date/Time: Thursday, September 18, 2025 @ 12:00 PM – 1:00 PM
-
Meeting ID: 259 562 780 510 8
|
